| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.11 | 0.5 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |